Physician profile

John A Shivdat

Emergency Medicine · Perry, GA

NPI 1376599746

$1,983.60

in general payments reported to CMS, 2019-2025

6 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Travel and Lodging$888.42
Food and Beverage$682.73

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Inari Medical, INC. $1,571.15 2024 Flowtriever Catheter, S, Ct Thrombectomy System Kit
Genentech, INC. $135.11 2019
Astrazeneca Pharmaceuticals Lp $124.44 2022
Dova Pharmaceuticals $124.10 2020
Depuy Synthes Sales INC. $17.03 2021
Abbott Laboratories $11.77 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

John A Shivdat

$1,983.60

in general payments reported 2019-2025

Years
2019-2024
Top company
Inari Medical, INC.

https://glasscript.com/doctor/17287/john-a-shivdat

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.